Elmind Capital LP Invests $5.54 Million in DBV Technologies S.A. $DBVT

Elmind Capital LP bought a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the 1st quarter, Holdings Channel.com reports. The firm bought 265,000 shares of the company’s stock, valued at approximately $5,536,000. DBV Technologies comprises approximately 1.6% of Elmind Capital LP’s holdings, making the stock its 19th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares in the last quarter. Truvestments Capital LLC raised its holdings in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after buying an additional 1,620 shares in the last quarter. Allworth Financial LP purchased a new position in shares of DBV Technologies during the 4th quarter valued at about $32,000. Royal Bank of Canada bought a new stake in DBV Technologies in the 4th quarter worth approximately $34,000. Finally, Persistent Asset Partners Ltd bought a new stake in DBV Technologies in the 4th quarter worth approximately $115,000. Institutional investors own 71.74% of the company’s stock.

Wall Street Analyst Weigh In

DBVT has been the subject of several analyst reports. Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Price Performance

DBVT stock opened at $13.90 on Tuesday. The stock’s fifty day moving average price is $16.45 and its 200-day moving average price is $19.29. The company has a market cap of $823.02 million, a P/E ratio of -3.96 and a beta of -0.95. DBV Technologies S.A. has a 1 year low of $8.51 and a 1 year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.90 million. As a group, analysts expect that DBV Technologies S.A. will post -2.05 earnings per share for the current year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.